« Today’s recommendation offers a glimmer of hope for the continent, which shoulders the heaviest burden of the disease, » said a WHO official.
LONDON — The world’s first malaria vaccine should be given to children across Africa, the World Health Organization recommended Wednesday, a move that officials hope will spur stalled efforts to curb the spread of the parasitic disease. WHO director-general Tedros Adhanom Ghebreyesus called it “a historic moment” after a meeting in which two of the U.N. health agency’s expert advisory groups endorsed using the vaccine. “Today’s recommendation offers a glimmer of hope for the continent, which shoulders the heaviest burden of the disease. And we expect many more African children to be protected from malaria and grow into healthy adults,” said Dr. Matshidiso Moeti, WHO’s Africa director. WHO said its decision was based largely on results from ongoing research in Ghana, Kenya and Malawi that tracked more than 800,000 children who have received the vaccine since 2019. The malaria vaccine known as Mosquirix was developed by GlaxoSmithKline in 1987. While it’s the first to be authorized, it does have challenges: the vaccine is only about 30% effective, requires up to four doses and its protection fades after several months. Still, given the extremely high burden of malaria in Africa — where the majority of the world’s more than 200 million cases a year and 400,000 deaths a year occur — scientists say the vaccine could still have a major impact. “This is a huge step forward,” said Julian Rayner, director of the Cambridge Institute for Medical Research, who was not part of the WHO decision. “It’s an imperfect vaccine, but it will still stop hundreds of thousands of children from dying.” Rayner said the vaccine’s impact on the spread of the mosquito-borne disease was still unclear, but pointed to coronavirus vaccines as an encouraging example.
